Comparison 1. Amisulpride versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Vomiting within 0 to 24 hours	2	841	Risk Ratio (IV, Random, 95% CI)	0.71 [0.52, 0.98]
1.1.1 Low dose	1	76	Risk Ratio (IV, Random, 95% CI)	0.83 [0.38, 1.80]
1.1.2 Recommended dose	2	694	Risk Ratio (IV, Random, 95% CI)	0.69 [0.38, 1.25]
1.1.3 High dose	1	71	Risk Ratio (IV, Random, 95% CI)	0.44 [0.19, 1.00]
1.2 Serious adverse events	2	904	Risk Ratio (IV, Random, 95% CI)	0.83 [0.38, 1.85]
1.2.1 Low dose	1	76	Risk Ratio (IV, Random, 95% CI)	0.97 [0.04, 22.74]
1.2.2 Recommended dose	2	757	Risk Ratio (IV, Random, 95% CI)	0.62 [0.11, 3.43]
1.2.3 High dose	1	71	Risk Ratio (IV, Random, 95% CI)	0.68 [0.07, 7.05]
1.3 Any adverse event	2	904	Risk Ratio (IV, Random, 95% CI)	0.97 [0.90, 1.06]
1.3.1 Low dose	1	76	Risk Ratio (IV, Random, 95% CI)	0.95 [0.75, 1.22]
1.3.2 Recommended dose	2	757	Risk Ratio (IV, Random, 95% CI)	0.98 [0.90, 1.08]
1.3.3 High dose	1	71	Risk Ratio (IV, Random, 95% CI)	0.93 [0.72, 1.20]
1.4 Headache	2	904	Risk Ratio (IV, Random, 95% CI)	1.56 [0.80, 3.08]
1.4.1 Low dose	1	76	Risk Ratio (IV, Random, 95% CI)	2.90 [0.16, 51.41]
1.4.2 Recommended dose	2	757	Risk Ratio (IV, Random, 95% CI)	1.50 [0.73, 3.06]
1.4.3 High dose	1	71	Risk Ratio (IV, Random, 95% CI)	1.76 [0.09, 35.02]
1.5 Sedation/drowsiness	1	689	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.5.1 Recommended dose	1	689	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.6 Extrapyramidal symptoms	1	689	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.6.1 Recommended dose	1	689	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.7 Constipation	2	904	Risk Ratio (IV, Random, 95% CI)	1.12 [0.71, 1.75]
1.7.1 Low dose	1	76	Risk Ratio (IV, Random, 95% CI)	0.93 [0.21, 4.22]
1.7.2 Recommended dose	2	757	Risk Ratio (IV, Random, 95% CI)	1.15 [0.70, 1.89]
1.7.3 High dose	1	71	Risk Ratio (IV, Random, 95% CI)	1.02 [0.23, 4.60]